An Open-Label Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Official Title

A Phase 2, Multicentre, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Summary:

The purpose of this study is to assess the objective response rate of parsaclisib treatment in subjects with relapsed or refractory follicular lymphoma.

Trial Description

Primary Outcome:

  • Objective response rate with parsaclisib based on Lugano classification response criteria
Secondary Outcome:
  • Complete response rate with parsaclisib based on Lugano classification response criteria
  • Duration of response
  • Progression-free survival with parsaclisib
  • Overall survival with parsaclisib
  • Safety and tolerability of parsaclisib measured by adverse events (AEs)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society